Pharmaceutical giant Novartis has paused several clinical trials following the deaths of three participants in Switzerland. The deaths are believed to be linked to a known complication arising from an experimental cell therapy. While details remain limited, the incidents prompted Novartis to temporarily halt the studies as a precautionary measure. The company is investigating the cases to determine the exact cause of death and assess the potential risks associated with the therapy. Patient safety is the priority, according to a Novartis statement, and further updates will be provided as the investigation progresses. This suspension affects multiple trial sites and underlines the inherent risks involved in pioneering medical treatments. The specific cell therapy and further details concerning the patients have not yet been disclosed.